Novo Nordisk A/s Earnings

Novo Nordisk A/s’s revenue jumped 12.93% since last year same period to $76857Mn in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -1.58% fall in its revenue since last 3-months.

Novo Nordisk A/s’s net profit jumped 32.18% since last year same period to $26503Mn in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -8.72% fall in its net profits since last 3-months.

Novo Nordisk A/s’s net profit margin jumped 17.05% since last year same period to 34.48% in the Q2 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -7.26% fall in its net profit margins since last 3-months.

Novo Nordisk A/s’s price-to-earnings ratio after this Q2 2025 earnings stands at 14.01.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current quarter stand at 5.34 - a -11% fall from last quarter’s estimates.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current year stand at 5.34.

Novo Nordisk A/s’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Novo Nordisk A/s has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Novo Nordisk A/s declared 0.58 dividend per share during the earnings announcement for Q3 2025.